J. Matous

Julie A. Murphy, M. Maris, P. Mcsweeney, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2014 .

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, P. Armand, S. Treon, 2015, Leukemia.

Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2013 .

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

Scott E. Smith, R. Advani, N. Bartlett, 2011 .

Safety and efﬁcacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Scott E. Smith, R. Advani, O. O’Connor, 2012 .

Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update

R. Advani, J. Connors, T. Illidge, 2011 .

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

M. Dimopoulos, C. Buske, S. Treon, 2018, The New England journal of medicine.

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort

I. Flinn, L. Hart, E. Faber, 2021, American journal of hematology.

Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient

S. Ingram, J. Matous, H. Schade, 2022, Oncology & Haematology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012, Blood.

Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2016 .

A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma

H. Goldschmidt, S. Lonial, R. Vij, 2008 .

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

F. Aguet, L. Trippa, A. Jakubowiak, 2022, Cancer cell.

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

M. Lunning, B. Holkova, A. Chari, 2018, Leukemia & lymphoma.

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

M. Lunning, R. Stuart, A. Chari, 2020, Hematological Oncology.

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

R. Advani, J. Connors, T. Illidge, 2010 .

Use of melphalan (M)/dexamethasone (D)/bortezomib in AL amyloidosis.

J. Abrams, C. Webb, J. Zonder, 2010 .

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

R. Advani, R. Bociek, J. Vose, 2014 .

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

D. Siegel, W. Pierceall, D. Reece, 2020, Leukemia.

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

D. Auclair, A. Jakubowiak, J. Laubach, 2018, Blood.

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

N. Munshi, J. Laubach, P. Richardson, 2018, Blood.

A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.

M. Dimopoulos, C. Buske, P. Marlton, 2020, Blood.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

J. Cortes, C. Abboud, G. Schiller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma

H. Ghazal, J. Berenson, S. Noga, 2013, Annals of Hematology.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Ash A. Alizadeh, R. Tibshirani, J. Vose, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

J. Berenson, J. Matous, H. Yeh, 2007, Clinical Cancer Research.

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010, American journal of hematology.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

R. Advani, J. Connors, T. Illidge, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

M. Dimopoulos, C. Buske, S. Treon, 2017, The Lancet. Oncology.

Prospective, Multicenter Study Of The Mtor Inhibitor Everolimus (RAD001) As Primary Therapy In Waldenstrom’s Macroglobulinemia

R. Advani, S. Treon, I. Ghobrial, 2011 .

Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.

P. Richardson, I. Ghobrial, S. Padmanabhan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

D. Siegel, D. Reece, A. Agarwal, 2020 .

Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.

D. Siegel, D. Reece, G. Schiller, 2018 .

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function

M. Dimopoulos, P. Sonneveld, D. Siegel, 2017, Clinical pharmacology : advances and applications.

Results of a Phase I Trial of SGN-40 (Anti-huCD40 mAb) in Patients with Relapsed Multiple Myeloma.

N. Munshi, J. Drachman, J. Berenson, 2006 .

Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia

I. Flinn, M. Maris, J. Matous, 2019, American journal of hematology.

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

P. Hari, M. Liedtke, O. Oluwole, 2020 .

Combination Trial of Duvelisib (IPI-145) with Bendamustine, Rituximab, or Bendamustine/Rituximab in Patients with Lymphoma or Chronic Lymphocytic Leukemia

I. Flinn, M. Maris, J. Matous, 2015 .

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

S. Treon, I. Ghobrial, Z. Hunter, 2016, Clinical Cancer Research.

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

N. Munshi, R. Sobecks, J. Drachman, 2010, Haematologica.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Scott E. Smith, R. Advani, O. O’Connor, 2012, Blood.

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results

M. Liedtke, Shaji K. Kumar, O. Oluwole, 2023, Nature Medicine.

Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2004 .

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010 .

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

M. Dimopoulos, C. Buske, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial

M. Dimopoulos, C. Buske, S. Treon, 2021, Clinical Cancer Research.

macroglobulinemia Long term outcomes to fludarabine and rituximab in Waldenstrom

P. Morel, S. Treon, A. Branagan, 2008 .

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2018, Blood.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.

R. Advani, S. Treon, Z. Hunter, 2005 .

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2020 .

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

S. Treon, I. Ghobrial, J. Castillo, 2015 .

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2009 .

MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

R. Vij, C. Rommel, I. Ghobrial, 2012 .

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Scott E. Smith, J. Friedberg, A. Younes, 2014, Leukemia & lymphoma.

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

S. Lonial, M. Dhodapkar, Robert A Emmons, 2019, Journal of Clinical Oncology.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carﬁlzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2012 .

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATETM)

M. Dimopoulos, C. Buske, S. Treon, 2015 .

Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial

M. Dimopoulos, C. Buske, S. Treon, 2020 .

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

P. Richardson, Shaji K. Kumar, D. Reece, 2009, British journal of haematology.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Sonali M. Smith, B. Cheson, Michael E. Williams, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial

D. Siegel, D. Reece, A. Agarwal, 2022, Leukemia & lymphoma.

Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

D. Siegel, D. Reece, A. Agarwal, 2018, Blood.

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

J. Laubach, P. Richardson, P. Armand, 2014 .

Phase I Trial of Pomalidomide, Bortezomib, and Dexamethasone As Frontline Treatment of AL Amyloidosis

S. Tuchman, V. Kukreti, J. Zonder, 2017 .

A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).

I. Flinn, L. Hart, E. Faber, 2015 .

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

S. Jagannath, D. Siegel, P. Hari, 2021, Blood.

Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

M. Liedtke, Shaji K. Kumar, O. Oluwole, 2023, Nature medicine.

Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab

D. Siegel, W. Pierceall, D. Reece, 2018, Blood.

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

D. Reece, A. Agarwal, G. Schiller, 2017 .

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

J. Goldberg, C. Touzeau, C. Hulin, 2022, Blood.

Dacetuzumab (SGN-40), Lenalidomide, and Weekly Dexamethasone in Relapsed or Refractory Multiple Myeloma: Multiple Responses Observed in a Phase 1b Study.

N. Munshi, J. Zonder, J. Drachman, 2009 .

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

M. Dimopoulos, C. Buske, V. Garg, 2021, Blood.

Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2011 .

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.

M. Dimopoulos, C. Buske, D. Macdonald, 2019, Journal of Clinical Oncology.

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

S. Lonial, P. Richardson, S. Horwitz, 2021, Blood.

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

J. Cortes, C. Abboud, G. Schiller, 2008 .

A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma.

J. Berenson, J. Matous, H. Yeh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment

S. Lonial, D. Siegel, R. Harvey, 2013 .

Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study)

J. Miguel, P. Richardson, N. Raje, 2016 .

MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).

D. Siegel, M. Zaki, J. Shah, 2013 .

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak, D. Siegel, P. Moreau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

G. Gudi, C. Huff, M. Mohty, 2022, Blood.

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

J. Abrams, C. Webb, J. Zonder, 2009 .

A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.

J. Berenson, J. Matous, H. Yeh, 2005 .

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

J. Matous, P. Shaughnessy, J. Berdeja, 2017 .

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

N. Munshi, R. Sobecks, J. Drachman, 2010, Haematologica.

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.

R. Advani, R. Bociek, J. Vose, 2018, Blood.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.

Scott E. Smith, R. Advani, O. O’Connor, 2012, Blood.

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

P. Richardson, S. Rodig, F. Azab, 2013, Blood.

CLINICAL TRIALS AND OBSERVATIONS Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, F. Azab, I. Ghobrial, 2017 .

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

M. Dimopoulos, C. Buske, P. Marlton, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

E. Kimby, P. Morel, S. Treon, 2008, Blood.

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

J. Laubach, P. Richardson, I. Ghobrial, 2018, Blood.

Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.

R. Advani, J. Connors, T. Illidge, 2012 .

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

R. Advani, J. Connors, T. Illidge, 2017, Blood.

Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients

Michael L. Wang, S. Jagannath, A. Jakubowiak, 2010 .

Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

R. Advani, M. Fanale, J. Matous, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.